Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer.

ABSTRACT:

Background

Pancreatic cancer is one of the most lethal malignancies due to frequent late diagnosis, aggressive tumor growth and metastasis formation. Continuously raising incidence rates of pancreatic cancer and a lack of significant improvement in survival rates over the past 30 years highlight the need for new therapeutic agents. Thus, new therapeutic agents and strategies are urgently needed to improve the outcome for patients with pancreatic cancer. Here, we evaluated the anti-tumor activity of a new natural product-based epidithiodiketopiperazine, NT1721, against pancreatic cancer.

Methods

We characterized the anticancer efficacy of NT1721 in multiple pancreatic cancer cell lines in vitro and in two orthotopic models. We also compared the effects of NT1721 to clinically

SUBMITTER: Kowolik CM 

PROVIDER: S-EPMC6819529 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature